tiprankstipranks
Trending News
More News >
Incyte Corp (INCY)
NASDAQ:INCY
US Market

Incyte (INCY) Stock Forecast & Price Target

Compare
1,716 Followers
See the Price Targets and Ratings of:

INCY Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
6 Buy
12 Hold
1 Sell
Based on 19 analysts giving stock ratings to
Incyte
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

INCY Stock 12 Month Forecast

Average Price Target

$72.36
▲(7.61%Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $72.36 with a high forecast of $89.00 and a low forecast of $52.00. The average price target represents a 7.61% change from the last price of $67.24.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","90":"$90","60.75":"$60.8","70.5":"$70.5","80.25":"$80.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$89.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$52.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,60.75,70.5,80.25,90],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.31,67.13230769230769,68.95461538461538,70.77692307692308,72.59923076923077,74.42153846153846,76.24384615384615,78.06615384615385,79.88846153846154,81.71076923076923,83.53307692307692,85.35538461538462,87.17769230769231,{"y":89,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.31,65.85230769230769,66.39461538461539,66.93692307692308,67.47923076923077,68.02153846153847,68.56384615384616,69.10615384615384,69.64846153846153,70.19076923076923,70.73307692307692,71.27538461538461,71.81769230769231,{"y":72.36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.31,64.28615384615385,63.262307692307694,62.23846153846154,61.214615384615385,60.190769230769234,59.16692307692308,58.143076923076926,57.11923076923077,56.09538461538462,55.07153846153846,54.04769230769231,53.02384615384615,{"y":52,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.79,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.87,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.42,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.13,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.16,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.31,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$89.00Average Price Target$72.36Lowest Price Target$52.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on INCY
TipRanks AITipRanks
Not Ranked
TipRanks
$69
Buy
2.62%
Upside
Reiterated
05/16/25
Incyte's stock score of 71 reflects a solid financial foundation and positive earnings call outcomes, highlighting strong revenue growth and product launches. However, the high P/E ratio suggests overvaluation, and recent legal settlements could impact financials. Technical indicators present a mixed outlook, with potential short-term strength but longer-term caution. While the company remains fundamentally strong, improving profitability and managing corporate challenges will be key to enhancing stock performance.
BMO Capital Analyst forecast on INCY
Evan SeigermanBMO Capital
BMO Capital
$52
Sell
-22.67%
Downside
Reiterated
06/04/25
BMO Capital Reaffirms Their Sell Rating on Incyte (INCY)
William Blair Analyst forecast on INCY
Matt PhippsWilliam Blair
William Blair
Hold
Reiterated
06/04/25
Incyte's Pipeline Developments: Balancing Promising Data with Uncertainties
Evercore ISI Analyst forecast on INCY
Unknown AnalystEvercore ISI
Not Ranked
Evercore ISI
$73
Hold
8.57%
Upside
Reiterated
06/04/25
Evercore ISI Reaffirms Their Hold Rating on Incyte (INCY)
J.P. Morgan Analyst forecast on INCY
Jessica FyeJ.P. Morgan
J.P. Morgan
$68
Hold
1.13%
Upside
Reiterated
06/03/25
Incyte (INCY) Gets a Hold from J.P. MorganJPMorgan analyst Jessica Fye reiterated a Neutral rating and $68.00 price target on Incyte (NASDAQ: INCY).
TD Cowen Analyst forecast on INCY
Marc FrahmTD Cowen
TD Cowen
$86
Buy
27.90%
Upside
Reiterated
06/03/25
TD Cowen Keeps Their Buy Rating on Incyte (INCY)
Citi
$88
Buy
30.87%
Upside
Reiterated
06/03/25
Incyte's Promising Clinical Trial Results and Favorable Safety Profile Drive Buy Rating with 34.7% Upside Potential
Stifel Nicolaus Analyst forecast on INCY
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
Hold
Reiterated
06/03/25
Incyte's Mixed Clinical Trial Results and Uncertainties Lead to Hold Rating
UBS
$61
Hold
-9.28%
Downside
Reiterated
06/03/25
UBS 'cautious' on Incyte's mCALR, says path to registration 'unclear' UBS 'cautious' on Incyte's mCALR, says path to registration 'unclear'
RBC Capital Analyst forecast on INCY
Brian AbrahamsRBC Capital
RBC Capital
$67
Hold
-0.36%
Downside
Reiterated
06/03/25
RBC says EHA late-breaking abstract shows Incyte may have drug in mCALR mAbRBC says EHA late-breaking abstract shows Incyte may have drug in mCALR mAb
Morgan Stanley Analyst forecast on INCY
Vikram PurohitMorgan Stanley
Morgan Stanley
$65$68
Hold
1.13%
Upside
Reiterated
06/03/25
Incyte's mCALR Program: Promising Early Data but Uncertainties Remain, Justifying Hold Rating
Leerink Partners Analyst forecast on INCY
Andrew BerensLeerink Partners
Leerink Partners
Buy
Reiterated
06/03/25
Incyte's Promising Drug Pipeline and INCA33989's Strong Performance Drive Buy Rating
Truist Financial Analyst forecast on INCY
Srikripa DevarakondaTruist Financial
Truist Financial
$72$73
Hold
8.57%
Upside
Reiterated
05/27/25
Truist Financial Keeps Their Hold Rating on Incyte (INCY)
Bank of America Securities Analyst forecast on INCY
Tazeen AhmadBank of America Securities
Bank of America Securities
$89
Buy
32.36%
Upside
Reiterated
05/14/25
Incyte (INCY) Receives a Buy from Bank of America Securities
Mizuho Securities Analyst forecast on INCY
Salim SyedMizuho Securities
Mizuho Securities
$77$70
Hold
4.10%
Upside
Reiterated
05/02/25
Mizuho Securities Keeps Their Hold Rating on Incyte (INCY)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on INCY
TipRanks AITipRanks
Not Ranked
TipRanks
$69
Buy
2.62%
Upside
Reiterated
05/16/25
Incyte's stock score of 71 reflects a solid financial foundation and positive earnings call outcomes, highlighting strong revenue growth and product launches. However, the high P/E ratio suggests overvaluation, and recent legal settlements could impact financials. Technical indicators present a mixed outlook, with potential short-term strength but longer-term caution. While the company remains fundamentally strong, improving profitability and managing corporate challenges will be key to enhancing stock performance.
BMO Capital Analyst forecast on INCY
Evan SeigermanBMO Capital
BMO Capital
$52
Sell
-22.67%
Downside
Reiterated
06/04/25
BMO Capital Reaffirms Their Sell Rating on Incyte (INCY)
William Blair Analyst forecast on INCY
Matt PhippsWilliam Blair
William Blair
Hold
Reiterated
06/04/25
Incyte's Pipeline Developments: Balancing Promising Data with Uncertainties
Evercore ISI Analyst forecast on INCY
Unknown AnalystEvercore ISI
Not Ranked
Evercore ISI
$73
Hold
8.57%
Upside
Reiterated
06/04/25
Evercore ISI Reaffirms Their Hold Rating on Incyte (INCY)
J.P. Morgan Analyst forecast on INCY
Jessica FyeJ.P. Morgan
J.P. Morgan
$68
Hold
1.13%
Upside
Reiterated
06/03/25
Incyte (INCY) Gets a Hold from J.P. MorganJPMorgan analyst Jessica Fye reiterated a Neutral rating and $68.00 price target on Incyte (NASDAQ: INCY).
TD Cowen Analyst forecast on INCY
Marc FrahmTD Cowen
TD Cowen
$86
Buy
27.90%
Upside
Reiterated
06/03/25
TD Cowen Keeps Their Buy Rating on Incyte (INCY)
Citi
$88
Buy
30.87%
Upside
Reiterated
06/03/25
Incyte's Promising Clinical Trial Results and Favorable Safety Profile Drive Buy Rating with 34.7% Upside Potential
Stifel Nicolaus Analyst forecast on INCY
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
Hold
Reiterated
06/03/25
Incyte's Mixed Clinical Trial Results and Uncertainties Lead to Hold Rating
UBS
$61
Hold
-9.28%
Downside
Reiterated
06/03/25
UBS 'cautious' on Incyte's mCALR, says path to registration 'unclear' UBS 'cautious' on Incyte's mCALR, says path to registration 'unclear'
RBC Capital Analyst forecast on INCY
Brian AbrahamsRBC Capital
RBC Capital
$67
Hold
-0.36%
Downside
Reiterated
06/03/25
RBC says EHA late-breaking abstract shows Incyte may have drug in mCALR mAbRBC says EHA late-breaking abstract shows Incyte may have drug in mCALR mAb
Morgan Stanley Analyst forecast on INCY
Vikram PurohitMorgan Stanley
Morgan Stanley
$65$68
Hold
1.13%
Upside
Reiterated
06/03/25
Incyte's mCALR Program: Promising Early Data but Uncertainties Remain, Justifying Hold Rating
Leerink Partners Analyst forecast on INCY
Andrew BerensLeerink Partners
Leerink Partners
Buy
Reiterated
06/03/25
Incyte's Promising Drug Pipeline and INCA33989's Strong Performance Drive Buy Rating
Truist Financial Analyst forecast on INCY
Srikripa DevarakondaTruist Financial
Truist Financial
$72$73
Hold
8.57%
Upside
Reiterated
05/27/25
Truist Financial Keeps Their Hold Rating on Incyte (INCY)
Bank of America Securities Analyst forecast on INCY
Tazeen AhmadBank of America Securities
Bank of America Securities
$89
Buy
32.36%
Upside
Reiterated
05/14/25
Incyte (INCY) Receives a Buy from Bank of America Securities
Mizuho Securities Analyst forecast on INCY
Salim SyedMizuho Securities
Mizuho Securities
$77$70
Hold
4.10%
Upside
Reiterated
05/02/25
Mizuho Securities Keeps Their Hold Rating on Incyte (INCY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

1 Month
xxx
Success Rate
13/22 ratings generated profit
59%
Average Return
+0.25%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.09% of your transactions generating a profit, with an average return of +0.25% per trade.
3 Months
xxx
Success Rate
19/34 ratings generated profit
56%
Average Return
+2.91%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.88% of your transactions generating a profit, with an average return of +2.91% per trade.
1 Year
Marc FrahmTD Cowen
Success Rate
24/34 ratings generated profit
71%
Average Return
+9.51%
reiterated a buy rating 4 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +9.51% per trade.
2 Years
xxx
Success Rate
15/22 ratings generated profit
68%
Average Return
+5.89%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.18% of your transactions generating a profit, with an average return of +5.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INCY Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
1
2
3
2
Buy
11
17
18
13
8
Hold
20
26
30
24
19
Sell
2
2
2
2
2
Strong Sell
0
0
0
0
0
total
33
46
52
42
31
In the current month, INCY has received 10 Buy Ratings, 19 Hold Ratings, and 2 Sell Ratings. INCY average Analyst price target in the past 3 months is 72.36.
Each month's total comprises the sum of three months' worth of ratings.

INCY Financial Forecast

INCY Earnings Forecast

Next quarter’s earnings estimate for INCY is $1.40 with a range of $1.06 to $1.78. The previous quarter’s EPS was $1.16. INCY beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year INCY has Outperformed its overall industry.
Next quarter’s earnings estimate for INCY is $1.40 with a range of $1.06 to $1.78. The previous quarter’s EPS was $1.16. INCY beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year INCY has Outperformed its overall industry.

INCY Sales Forecast

Next quarter’s sales forecast for INCY is $1.15B with a range of $1.13B to $1.19B. The previous quarter’s sales results were $1.05B. INCY beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year INCY has Outperformed its overall industry.
Next quarter’s sales forecast for INCY is $1.15B with a range of $1.13B to $1.19B. The previous quarter’s sales results were $1.05B. INCY beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year INCY has Outperformed its overall industry.

INCY Stock Forecast FAQ

What is INCY’s average 12-month price target, according to analysts?
Based on analyst ratings, Incyte Corp’s 12-month average price target is 72.36.
    What is INCY’s upside potential, based on the analysts’ average price target?
    Incyte Corp has 7.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is INCY a Buy, Sell or Hold?
          Incyte Corp has a consensus rating of Moderate Buy which is based on 6 buy ratings, 12 hold ratings and 1 sell ratings.
            What is Incyte Corp’s price target?
            The average price target for Incyte Corp is 72.36. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $89.00 ,the lowest forecast is $52.00. The average price target represents 7.61% Increase from the current price of $67.24.
              What do analysts say about Incyte Corp?
              Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of INCY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis